Lamotrigine Tablet
Product Images NDC 68071-3944

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Lamotrigine (NDC 68071-3944). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3944 6)

Packaging label for Lamotrigine 100 mg tablets by NuCare Pharmaceuticals, Inc. The label specifies a quantity of 60 tablets, with each scored, light peach, round tablet engraved "TARO" on one side and "LMT" and "100" on the other. It includes the NDC 68071-3944-6 and storage instructions at 68-77°F, with warnings to keep out of reach of children.*

FDA Label Image

Tabs (Lamo Tabs Med Guid Pg2)

This image contains detailed safety information related to lamotrigine tablets, including warnings about stopping the medication suddenly, possible side effects like aseptic meningitis symptoms, and the importance of verifying the correct medication due to similar drug names. At the bottom, images and descriptions of Lamotrigine Tablets USP in 25 mg, 100 mg, 150 mg, and 200 mg strengths are shown, illustrating their color, shape, scoring, and engraved markings for identification.*

FDA Label Image

Tabs (Lamo Tabs Med Guide Pg1)

This medication guide for Lamotrigine tablets, USP, provides detailed warnings about serious side effects. Key points include the risk of serious skin rashes potentially leading to hospitalization or death, risks of serious blood or liver problems, possible heart-related issues, and mental health warnings about suicidal thoughts and behavior. It advises patients to promptly report symptoms such as skin rash, fever, unusual bruising, heart palpitations, depression, and others to their healthcare provider.*

FDA Label Image

Tabs (Lamo Tabs Med Guide Pg 4)

Text panel from the Medication Guide for Lamotrigine tablets describing overdose instructions, warnings about seizure management, swallowing instructions, blister pack examination, activity precautions, common side effects, storage instructions, and general safe use information. The panel lists inactive ingredients and provides contact information for additional questions. The guide is approved by the FDA.*

FDA Label Image

Tabs (Lamo Tabs Med Guide Pg.3.5)

Text panel titled 'How should I take lamotrigine tablets?' providing instructions for lamotrigine use. It advises taking lamotrigine exactly as prescribed, consulting a healthcare provider before changing dose or stopping the medication, and guidance on missed doses, emphasizing not to take two doses simultaneously.*

FDA Label Image

Tabs (Lamo Tabs Med Guide Pg3)

This image shows a text excerpt titled 'What is lamotrigine?' which includes detailed information about lamotrigine's uses, safety considerations, and warnings. It lists conditions for which lamotrigine is prescribed, cautions about safety in certain populations, and advises patients on what to discuss with healthcare providers before taking lamotrigine tablets.*

FDA Label Image

Chemical Structure (Lamotrigine 01)

Chemical structure of lamotrigine shown as a molecular diagram with rings and chlorine, nitrogen, and amino groups clearly illustrated.*

FDA Label Image

Figure 1 (Lamotrigine 02)

A Kaplan-Meier failure probability chart comparing Lamotrigine and placebo over weeks, showing percentage failure probability on the vertical axis and time in weeks on the horizontal axis. The chart includes censored data points and illustrates two distinct curves labeled Lamotrigine and Placebo.*

FDA Label Image

Figure 2 (Lamotrigine 03)

A Kaplan-Meier failure probability plot showing the comparison between Lamotrigine and placebo over a period of approximately 80 weeks. The y-axis represents Failure Probability (%) and the x-axis shows Weeks. Two distinct curves are labeled Lamotrigine and Placebo, illustrating differences in failure rates over time. Censored data points are marked on both curves.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.